Articles From: Seaspan Announces Conference Call and Webcast to Discuss Results for the Third Quarter Ended September 30, 2014 to SEC charges scientific instrument company with paying Chinese officials


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0975008001&sourceType=1 http://www.ccnmatthews.com/logos/20080327-SEALOGO.JPG HONG KONG, CHINA --
Sign-up for Seaspan Announces Conference Call and Webcast to Discuss Results for the Third Quarter Ended September 30, 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G030278-001&sourceType=1 http://www.marketwire.com/library/MwGo/2015/1/13/11G030278/seaspan_logo-114676605876.jpg HONG KONG, CHINA--(Marketwired - January 13, 2015) - Seaspan Corporation (NYSE: SSW) announced today that the Company's Board of Directors has declared cash dividends on its common and preferred shares as follows: About Seaspan Seaspan provides many of the world's major shipping lines with creative outsourcing alternatives to vessel ownership by offering long-term leases on large, modern containerships combined with industry leading ship management services.
Sign-up for Seaspan Declares Quarterly Dividends on Common and Preferred Shares investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0976685001&sourceType=1 http://www.ccnmatthews.com/logos/20080327-SEALOGO.JPG HONG KONG, CHINA --
Sign-up for Seaspan Reports Financial Results for the Three and Nine Months Ended September 30, 2014 investment picks
Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials.
Sign-up for Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.
Sign-up for Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
Sign-up for Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted multiple ADCETRIS (brentuximab vedotin) data presentations in frontline and salvage Hodgkin lymphoma (HL) at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA, December 6-9, 2014.
Sign-up for Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia (AML). The trial will also evaluate SGN-CD33A in the consolidation setting for AML, both in combination with cytarabine and as a single-agent maintenance regimen.
Sign-up for Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia investment picks
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Jean I.
Sign-up for Seattle Genetics Names New General Counsel and Executive Vice President, Legal Affairs investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from two ongoing phase 1 clinical trials evaluating SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA December 6-9, 2014.
Sign-up for Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the third quarter and nine months ended September 30, 2014.
Sign-up for Seattle Genetics Reports Third Quarter 2014 Financial Results investment picks
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets.
Sign-up for Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015 investment picks
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 11, 2014, at 8:30 a.m. Mountain Time.
Sign-up for Seattle Genetics to Present at Credit Suisse Healthcare Conference investment picks
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.
Sign-up for Seattle Genetics to Present at the J.P. Morgan Healthcare Conference investment picks
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, California, December 6-9, 2014, highlighting the following: “Antibody-drug conjugates represent an innovative and important therapeutic approach to targeting cancer.
Sign-up for Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 investment picks
2014/11/6
Whether searching for deals online from home or on-the-go, more than half of holiday shoppers say a cup of coffee is their favorite way to prepare for a day of shopping.
Sign-up for Seattle’s Best Coffee Offers Doorbuster Giveaways for Earlybird Holiday Shoppers investment picks
2014/12/11
By Maria Armental SeaWorld Entertainment Inc. said Jim Atchison will depart as chief executive, and the theme-park operator unveiled a restructuring plan that comes as it has faced controversy over its treatment of killer whales.
Sign-up for SeaWorld CEO to depart as theme-park operator plans restructuring investment picks
- Program Start Date Accelerated to December 17, 2014 - - Authorizes Repurchases of Up to $15 Million for Remainder of Calendar Year 2014 - ORLANDO, Fla.
Sign-up for SeaWorld Entertainment, Inc. Announces Amendment of Existing Share Repurchase Program investment picks
- Jim Atchison Becomes Vice Chairman; Board Launches Search for Permanent CEO - - Two New Independent Directors Appointed to Board - ORLANDO, Fla.
Sign-up for SeaWorld Entertainment, Inc. Announces David D'Alessandro Named Interim CEO investment picks
ORLANDO, Fla.
Sign-up for SeaWorld Entertainment, Inc. Announces Quarterly Dividend investment picks
ORLANDO, Fla.
Sign-up for SeaWorld Entertainment, Inc. Reports Third Quarter 2014 Results investment picks
Shares of SeaWorld Entertainment (SEAS) slumped 5.9% in premarket trade Wednesday, after the theme park operator reported third-quarter profit that fell short of forecasts.
Sign-up for SeaWorld's stock drops after profit miss, potential dividend delay investment picks
2014/12/16
Baby Animals, Big Cats, Kids Network, Penguins and Polar Bears will each be available for free download in the App Store.
Sign-up for SeaWorld® Kids Explores Nature With Five New, Fun Mobile Apps investment picks
2014/10/24
The Securities and Exchange Commission on Friday announced insider trading charges against David Post of Livingston, N.J., who generated nearly $700,000 in illicit profits after receiving tips that two pharmaceutical companies were about to be acquired.
Sign-up for SEC announces insider trading charges for N.J. man for pharmaceutical acquisition knowledge investment picks
2015/1/13
The Securities and Exchange Commission announced the members of its Equity Market Structure Advisory Committee on Tuesday.
Sign-up for SEC announces members of new market structure committee investment picks
By Steve Goldstein, MarketWatch WASHINGTON (MarketWatch) -- The Securities and Exchange Commission on Thursday announced its third case in four days over alleged high-frequency trading abuses, this time charging UBS with not disclosing an order type that allowed some traders to jump ahead of others.
Sign-up for SEC brings third high-frequency trading case in four days investment picks
WASHINGTON (MarketWatch)--The Securities and Exchange Commission charged Bio-Rad Laboratories (BIO) , a clinical diagnostic and life-science research company, with violating the Foreign Corrupt Practices Act.
Sign-up for SEC charges Bio-Rad Laboratories with bribery violations investment picks
A Santa Monica-based stock promoter has been charged with fraudulently raising nearly $3.5 million from investors to purchase Facebook (FB) and Twitter (TWTR) stocks before their initial public offerings.
Sign-up for SEC charges California stock promoter for defrauding investors for Facebook and Twitter shares investment picks
2014/12/15
A Massachusetts-based scientific instruments manufacturer has been charged with providing related travel expenses to Chinese government officials.
Sign-up for SEC charges scientific instrument company with paying Chinese officials investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Seaspan Announces Conference Call and Webcast to Discuss Results for the Third Quarter Ended September 30, 2014 to SEC charges scientific instrument company with paying Chinese officials
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent